Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

07 / Pharmacology

How long compounds take to reach steady state

Reference documentation on how these compounds are regulated, supplied and studied. Not a vendor assessment, not a recommendation, and not personal-use instructions.

Two different clocks get collapsed into this question, and they differ by an order of magnitude. The pharmacokinetic clock is how long repeated dosing takes to reach a stable concentration, which is about five half-lives and is calculable for any compound with a published half-life. The clinical clock is how long a trial had to run before an effect was measurable, which is known only where a trial exists. For semaglutide the first is roughly five weeks and the second was 68 weeks. Reaching steady state is a statement about blood concentration and says nothing about whether anything is working.

The pharmacokinetic clock

With repeated dosing at a fixed interval, concentration accumulates until the amount cleared between doses equals the amount given. That point is steady state, and it arrives after roughly four to five half-lives regardless of the dose. A larger dose reaches a higher steady concentration, not a faster one. The distribution below is every compound in this catalog grouped by its reported half-life, with the steady-state horizon that follows from it.

Scope. This applies only to repeated dosing at a fixed interval. A single administration has no steady state, and a compound with a half-life of minutes is cleared long before the next dose.

All 110 catalogued compounds by reported half-life. 71 carry a numeric figure.
Reported half-lifeCountSteady state under repeated dosing
Under an hour40Steady state within a few hours, and the compound is effectively cleared between doses.For example: Tesamorelin, Semax, Selank, AOD-9604.
One to twelve hours14Steady state within about two days of repeated dosing.For example: BPC-157, Ipamorelin, Thymosin Alpha-1, Dihexa.
Twelve hours to two days5Steady state within roughly a week to ten days.For example: TB-500, MK-677, IGF-1 LR3, Liraglutide.
Two to seven days10Steady state after roughly four to five weeks of weekly dosing.For example: Tirzepatide, Semaglutide, Retatrutide, PEG-MGF.
Longer than a week2Steady state after more than a month, and often longer.For example: Tesofensine, Testosterone Cypionate.
Blend, half-life belongs to the components7A combination. Each component clears at its own rate, so the blend has no single half-life and no single steady-state horizon.For example: Wolverine, CJC-1295 + Ipamorelin, Tesamorelin + Ipamorelin, BPC-157 + KPV.
Topical, no systemic figure15Applied to the skin and acting locally. A plasma half-life is not the quantity that governs the effect.For example: AHK-Cu, Argireline, Decapeptide-12, Matrixyl.
Depot or implant2Release from the formulation is slower than clearance, so the formulation sets the duration rather than the half-life.For example: Triptorelin, Melanotan I.
Two forms with different half-lives1The compound ships in more than one form and the forms clear at different rates, so a single steady-state horizon would describe neither.For example: CJC-1295.
Not established14No half-life has been published for this compound, in humans or at all. No steady-state horizon can be stated.For example: GHK-Cu, FOXO4-DRI, Humanin, PNC-27.

The clinical clock, where a trial exists

The compounds below carry a registration or Phase 2 readout in this catalog, so both clocks are known for them. The gap between the two columns is the answer to the question. In every case the trial ran for many multiples of the time needed to reach a stable concentration, because what the trial was measuring was a slow physiological change rather than the arrival of the drug in plasma.

The 20 catalogued compounds carrying both a published half-life and a controlled trial of known duration. A further 5 have a trial but no usable half-life.
CompoundHalf-lifeTo steady stateTrial lengthRatioWhat the trial measured
Semaglutide~7 days35 days208 weeks41.6xweight loss, n=8803PMID:38740993
SS-31~2-4 hrs19.2 hours168 weeks1176xmitochondrial functionPMID:38602181
Tirzepatide~5 days25 days88 weeks24.6xfat loss, n=335PMID:38078870
Orforglipron~29-49 hrs10.2 days72 weeks49.4xweight loss, n=3127PMID:40960239
CagriSema~7 days35 days68 weeks13.6xweight loss, n=2108PMID:40544433
Liraglutide~13 hrs2.7 days56 weeks144.7xweight loss, n=423PMID:26284720
MK-677~24 hrs5 days52 weeks72.8xIGF-1 changePMID:19015485
Somatropin (HGH)~2-5 hrs (SC)1 day52 weeks349.4xgrowth velocityPMID:36062966
Retatrutide~6 days30 days48 weeks11.2xweight loss, n=70PMID:37366315
MazdutideLong-acting weekly35 days48 weeks9.6xweight loss, n=203PMID:40421736
SurvodutideLong-acting weekly35 days48 weeks9.6xMASH resolution, n=73PMID:38847460
Dulaglutide~5 days25 days40 weeks11.2xHbA1c reduction, n=299PMID:29397376
Cagrilintide~7 days35 days32 weeks6.4xweight loss, n=30PMID:37364590
Tesamorelin~26 min2.4 hours26 weeks182xvisceral fat reduction, n=806PMID:20554713
Sermorelin~10-20 min2.4 hours26 weeks182xgrowth velocity, n=86PMID:8772599
PT-141~2 hrs9.6 hours24 weeks168xsexual desire scorePMID:31599840
CerebrolysinShort (minutes-hours)2.4 hours13 weeks91xstroke recovery ratePMID:40325343
Testosterone Cypionate~8 days (cypionate ester)40 days12 weeks2.1xbody compositionPMID:40177735
Enclomiphene~10 hrs2.1 days6 weeks20.2xtestosterone increase, n=48PMID:23875626
ARA-290~2 hrs9.6 hours4 weeks28xneuropathy pain reductionPMID:23168581

Where neither clock is known

Most of this catalog has no trial readout at all, and for those compounds no honest figure for time to effect exists. A published half-life still gives a steady-state horizon, which is a real number about concentration, and that is the most that can be said. Any source offering a "results in two to four weeks" figure for a compound with no controlled trial is describing expectation rather than evidence.

Frequently asked questions

How long do peptides take to work?

It depends on which of two clocks is meant, and they differ by an order of magnitude. Time to steady state, meaning the point at which repeated dosing produces a stable blood concentration, is about five half-lives: a few hours for a compound cleared in minutes, and four to five weeks for one with a half-life of several days. Time to a measurable clinical effect is a separate question answered only by trials. Semaglutide reaches steady state in roughly five weeks, and the STEP 1 trial that established its weight-loss effect ran for 68 weeks. Reaching steady state is not the same as an effect appearing.

What is time to steady state, and how soon after starting is it reached?

Steady state is the point at which the amount of a compound cleared between doses equals the amount administered, so the concentration stops rising. With dosing at a fixed interval it arrives after roughly four to five half-lives, independent of the dose size. For a compound with a half-life of about seven days, dosed weekly, that is roughly five weeks. For one with a half-life of two hours it is under a day.

Does a higher dose reach steady state faster?

No. The time to steady state is set by the half-life and the dosing interval, not by the dose. A larger dose settles at a higher concentration after the same number of half-lives. This is why loading schemes exist in clinical practice: they raise the starting concentration rather than shortening the accumulation period.

Sources

Open this guide on PeptideHelper.org for the interactive version with the full guide series navigation.